US FDA Turns To Temporary Enforcement Discretion For Boosting Infant Formula Supply

Agency Also Allows Abbott Facility To Restart Production Under Consent Decree

FDA launches temporary enforcement discretion on infant formula product to help increase supply in US on same day consent decree announced to allow Abbott to restart production at facility closed since February, prompting ongoing formula shortage. 

• Source: Shutterstock

The US Food and Drug Administration allows Abbott Laboratories Ltd. to restart production at its Sturgis, MI, infant formula plant a consent decree on steps necessary while also launching temporary enforcement discretion to encourage production from other firms to eliminate shortage.

More from Regulation

More from Policy & Regulation